ImmuCell Corporation
corporate_fare Company Profile
ImmuCell Corporation (NASDAQ:ICCC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ICCC at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- ImmuCell Reports $3.6M Impairment on Re-Tain® After FDA Setback, Shifts Focus to First Defense® Amid Mixed Sales
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$27.64M
Net Income
-$1.04M
Diluted EPS
-$0.12
Op. Cash Flow
$2.48M
Free Cash Flow
$1.22M
Gross Profit
$11.45M
Operating Income
$1.65M
Cash & Equivalents
$3.81M
Total Debt
$9.1M
Debt / Equity
0.34×
Net Margin
-3.8%
Shares Outstanding
9.05M sh
Source: 10-K · filed 2026-05-13 · accession 0001437749-26-016719
show_chartPrice Chart
Loading chart...
feed ICCC - Filings & News (Page 2)
ICCC
Jan 08, 2026, 4:13 PM EST
Price at Filing:
$6.57
Real-time Price:
$10.92
Change:
+$4.35 (+66%)
Market Cap:
$99.278M